Receptor pharmacology or animal models for dose selection in humans? Bart Laurijssens Clinical Pharmacology Modelling & Simulation, GlaxoSmithKline, UK
Satellite Meeting on Predictive Modelling in Drug DevelopmentPAGE, St Petersburg, 23 June 2009
2
Animal Models?
Pharmacology
3
Predictive Modelling in Early Development.
A Simulation exercise: Extrapolation! May include some analysis of data.
Prediction of Dose Pharmacological Clinical
HUMAN DOSE!
4
Why predicting Human Clinical Dose early?
[adapted from: Jennifer Sims, ABPI/BIA Early Clinical Trials Taskforce, slideset]
TI
5
-5%
5%
15%
25%
35%
45%
0.1 0.3 1 3 10 30 100 300 1000 3000
Dose (mg)
Pro
bab
ility
Parameter Guess Low High
MWT 450 250 700
Kd(nM) 1 0.3 100
Clinical 10 3 100
CL(ml/min) 200 3 1000
F (%) 64% 5% 95%
Tau (hrs) 12 6 24
No priorknowledge!
The Dose is RightPharma’s Favourite Game Show
BobBarker
Why is the dose “mg” not grams or “ng”? The screening process naturally selects candidates that drive the dose range A model can help
Dose MWT Kd Clinical CL/F
[thanks to Daren Austin]
Predicting Human Dose? Simple.
6
Mechanistic Classification of Biomarkers
Ease to Predict
Clinical Relevance of Prediction?
?
7
DRUG
Affinity
IntrinsicEfficacy
SYSTEM Slope
Potency
IntrinsicActivity
Tissue species gender
DiseaseAge
chronic treatment combined treatment
Pharmacodynamic Theory
[Van der Graaf & Danhof, 1998]
8
Species differences in Receptors
9
So what about Animal Models of Disease?
Face Validity Phenomenological Similarities with the disorder
Predictive Validity Need drugs that work Quantitative False positives/negatives Mechanism specific?
Construct Validity Sound theoretical rationale Need to understand disease and animal
10
What information to look for?
Distribution to target(s) in Humans: Transporters (eg PgP) Extracellular vs Intracellular target
Interaction with the Human Target(s) Affinity (in vitro, ex vivo) Efficacy (agonism vs antagonism)
Human pharmacology In vitro, ex vivo Animal models of physiology (or Disease) Time course of response
Knowledge Experience with mechanism in Humans Human physiology General Pharmacological Theory
11
Human PK-RO was predicted using: Rat ex-vivo RO for R1 Rat and Human in-vitro Binding
(R1 and R2) Rat and Human Fu, B:P Assumption re. PgP
Using Receptor Occupancy for a new target
12
Using Receptor Occupancy for a new target
Compound Dose (mg)
1 10 100
Ta
rge
t R
ec
ep
tor
oc
cu
pa
nc
y (
%,
95
% C
I)
0
10
20
30
40
50
60
70
80
90
100
NT
re
late
d r
es
po
ns
e (
%)
0
10
20
30
40
50
60
70
80
90
100
Target Receptor Occupancy
NT related response
Minimal “response” during dosing interval at steady state2] Do not study doses with <80% RO
3] Doses that hardly separate based on RO, potentially separate in efficacy
[Page satellite meeting, Pamplona, 2005]
1] =theoretical range of efficacy:No suppression – No effectMax suppression – Max effect
13
Total Unbound
Ketorolac
Fenoprofen
Naproxen
Rofecoxib
Using primary Human Pharmacology and Clinical Knowledge
[Huntjens et al. Rheumatology 2005;44:846–859]
14 Primary Pharmacology different Human vs Animal Gone horribly wrong
X
15Receptor Occupancy of TGN1412 at starting Dose
[Jennifer Sims, ABPI/BIA Early Clinical Trials Taskforce, slideset]
16
Mechanism of Action of TGN1412
17
Predictive animal model
[Rocchetti et al. Eur J Cancer 43 (2007): 1862-8]
18
19
Conclusions
It is not about animal models vs receptor occupancy, but about what data is informative.
Only informative data is worthy of your modelling skills and time.
Animal Models MAY be informative
Human Target Receptor Occupancy, or if possible, Target (in)Activation, is always informative.
And … nearly always available.
HUMAN dose!
20
My Favourite Animal Model